Abstract
Scientists have tried for many years to understand cancer development and progression in the expectation of defining the therapeutic target. Emerging evidence has revealed that cancers contain a minority population, termed “Cancer stem cells (CSCs)”, which are responsible for sustaining the tumour as well as giving rise to proliferating cells. CSCs are thought share the three features with normal stem cells: self-renewal, the capability give rise to multiple lineages, the potential to proliferate extensively and therefore it has been proposed that they have their origin in normal stem cells. However, since there is evidence that genetic alterations occurring in committed progenitor cells can reactive their proliferative potential, the origin of CSCs still remains undecided. In this review, we discuss the current status of cancer stem cells in various tissues, the origin of some cancers from normal stem cells, the evidence for the existence of particular markers and aspects of their cell biology. Better understanding of the relation between adult stem cells and cancer stem cells in tumourigenesis may will provide novel therapeutic strategies against cancers.
Keywords: Stem cells, cancer stem cells, side population (SP), non-SP, tumourigenesis, mitochondria
Current Cancer Therapy Reviews
Title: Cancer and Stem Cells
Volume: 4 Issue: 3
Author(s): Lydia Gutierrez-Gonzalez, Osamu Inatomi, Julia Burkert and Nichoals A. Wright
Affiliation:
Keywords: Stem cells, cancer stem cells, side population (SP), non-SP, tumourigenesis, mitochondria
Abstract: Scientists have tried for many years to understand cancer development and progression in the expectation of defining the therapeutic target. Emerging evidence has revealed that cancers contain a minority population, termed “Cancer stem cells (CSCs)”, which are responsible for sustaining the tumour as well as giving rise to proliferating cells. CSCs are thought share the three features with normal stem cells: self-renewal, the capability give rise to multiple lineages, the potential to proliferate extensively and therefore it has been proposed that they have their origin in normal stem cells. However, since there is evidence that genetic alterations occurring in committed progenitor cells can reactive their proliferative potential, the origin of CSCs still remains undecided. In this review, we discuss the current status of cancer stem cells in various tissues, the origin of some cancers from normal stem cells, the evidence for the existence of particular markers and aspects of their cell biology. Better understanding of the relation between adult stem cells and cancer stem cells in tumourigenesis may will provide novel therapeutic strategies against cancers.
Export Options
About this article
Cite this article as:
Gutierrez-Gonzalez Lydia, Inatomi Osamu, Burkert Julia and Wright A. Nichoals, Cancer and Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294249
DOI https://dx.doi.org/10.2174/157339408785294249 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Light Deficiency Confers Breast Cancer Risk by Endocrine Disorders
Recent Patents on Anti-Cancer Drug Discovery Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Editorial [Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites (Guest Editor: Milen I. Georgiev)]
Current Medicinal Chemistry Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
Current Drug Metabolism Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Genetic Polymorphisms in Metabolism of Carcinogenic Heterocyclic Aromatic Amines
Current Drug Metabolism Chitosan Nanoparticles as a Novel Drug Delivery System: A Review Article
Current Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design